Clinical Outcomes and Routine Management of Adults With Chronic Lymphocytic Leukaemia Treated With Idelalisib and Rituximab in the United Kingdom (UK) and Ireland

Sponsor
Gilead Sciences
Study ID
NCT03582098
Status
Completed

Conditions

  • Chronic Lymphocytic Leukaemia

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Idelalisib — DRUG
    Tablets were administered in accordance with the marketing authorization.
  • Rituximab — DRUG
    Tablets were administered in accordance with the marketing authorization.

Study Details

The primary objective of this study is to evaluate the effectiveness of idelalisib and rituximab in adults with chronic lymphocytic leukaemia (CLL) in a real world setting

Key Dates

Start date
Sep 12, 2018
Status verified
Apr 2019
Primary completion
Mar 26, 2019
Completion
Mar 26, 2019

Study Design

Enrollment
112 participants (actual)

Arms

  • Arm: Idelalisib and Rituximab
    Individuals who received treatment for CLL with at least one dose of idelalisib and rituximab in accordance with the marketing authorisation.

Primary Outcome Measure

Overall Response Rate [ Time Frame: Up to 3 months ]

Related Studies